Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial.

Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, Lilac HA, Hall H, Klimov A, Fukuda K.

JAMA. 2000 Oct 4;284(13):1655-63.

PMID:
11015795
2.

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.

Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, Glezen WP, Wittes J.

JAMA. 1999 Jul 14;282(2):137-44.

PMID:
10411194
3.

The effectiveness of vaccination against influenza in healthy, working adults.

Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M, Magnan S, Drake M.

N Engl J Med. 1995 Oct 5;333(14):889-93.

4.

Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age.

Allsup S, Gosney M, Haycox A, Regan M.

Health Technol Assess. 2003;7(24):iii-x, 1-65.

5.

Effectiveness of influenza vaccine in health care professionals: a randomized trial.

Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC.

JAMA. 1999 Mar 10;281(10):908-13.

PMID:
10078487
6.

Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children.

Luce BR, Zangwill KM, Palmer CS, Mendelman PM, Yan L, Wolff MC, Cho I, Marcy SM, Iacuzio D, Belshe RB.

Pediatrics. 2001 Aug;108(2):E24.

PMID:
11483834
7.

Cost-effectiveness of the influenza vaccine in a healthy, working-age population.

Campbell DS, Rumley MH.

J Occup Environ Med. 1997 May;39(5):408-14.

PMID:
9172085
9.
10.

Seasonal influenza vaccination of healthy working-age adults: a review of economic evaluations.

Gatwood J, Meltzer MI, Messonnier M, Ortega-Sanchez IR, Balkrishnan R, Prosser LA.

Drugs. 2012 Jan 1;72(1):35-48. doi: 10.2165/11597310-000000000-00000. Review.

PMID:
22191794
11.
12.
14.

Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.

Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ.

Vaccine. 2008 Jun 2;26(23):2841-8. doi: 10.1016/j.vaccine.2008.03.046. Epub 2008 May 6.

PMID:
18462851
15.

Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.

Chit A, Becker DL, DiazGranados CA, Maschio M, Yau E, Drummond M.

Lancet Infect Dis. 2015 Dec;15(12):1459-66. doi: 10.1016/S1473-3099(15)00249-2. Epub 2015 Sep 8.

PMID:
26362172
16.

Economic costs of influenza-related work absenteeism.

Akazawa M, Sindelar JL, Paltiel AD.

Value Health. 2003 Mar-Apr;6(2):107-15.

17.

Economic analysis of influenza vaccination and antiviral treatment for healthy working adults.

Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED.

Ann Intern Med. 2002 Aug 20;137(4):225-31.

PMID:
12186512
18.

Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.

Postma MJ, Jansema P, van Genugten ML, Heijnen ML, Jager JC, de Jong-van den Berg LT.

Drugs. 2002;62(7):1013-24. Review.

PMID:
11985488
19.

Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50-64 years.

Nichol KL, D'Heilly SJ, Greenberg ME, Ehlinger E.

Clin Infect Dis. 2009 Feb 1;48(3):292-8. doi: 10.1086/595842.

PMID:
19115970
20.

Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients.

Wongsurakiat P, Lertakyamanee J, Maranetra KN, Jongriratanakul S, Sangkaew S.

J Med Assoc Thai. 2003 Jun;86(6):497-508.

PMID:
12924797

Supplemental Content

Support Center